litlas
Log inCreate account

Michael W. Deininger

Active 1997–2025

161
Papers
42,917
Citations
97
h-index
160
i10-index

Citations

Citations per year for Michael W. Deininger1975: 1 citations1979: 6 citations1998: 3 citations1999: 15 citations2000: 31 citations2001: 36 citations2002: 118 citations2003: 157 citations2004: 125 citations2005: 173 citations2006: 228 citations2007: 301 citations2008: 307 citations2009: 315 citations2010: 309 citations2011: 306 citations2012: 297 citations2013: 360 citations2014: 353 citations2015: 340 citations2016: 321 citations2017: 283 citations2018: 287 citations2019: 1,025 citations2020: 1,246 citations2021: 1,220 citations2022: 1,060 citations2023: 628 citations2024: 1,280 citations2025: 469 citations2026: 13 citations1976–1978: no citations, so these years are not shown1980–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,467 citing papers, 27.7% of this breakdownGermany: 929 citing papers, 7.4% of this breakdownUnited Kingdom: 856 citing papers, 6.8% of this breakdownChina: 852 citing papers, 6.8% of this breakdownItaly: 845 citing papers, 6.8% of this breakdownFrance: 656 citing papers, 5.2% of this breakdownCanada: 412 citing papers, 3.3% of this breakdownSwitzerland: 363 citing papers, 2.9% of this breakdownAustralia: 346 citing papers, 2.8% of this breakdownSpain: 340 citing papers, 2.7% of this breakdownJapan: 296 citing papers, 2.4% of this breakdownNetherlands: 282 citing papers, 2.3% of this breakdown
0%27.7%Other 22.9%

Institutions

Fields

  • Medicine74%
  • Biochemistry, Genetics and Molecular Biology18.2%
  • Immunology and Microbiology3.3%
  • Computer Science1.7%
  • Chemistry0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Other1.7%

Topics

  • Chronic Myeloid Leukemia Treatments12.6%
  • Acute Myeloid Leukemia Research8.5%
  • Chronic Lymphocytic Leukemia Research6.4%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment5.7%
  • Eosinophilic Disorders and Syndromes5.7%
  • Acute Lymphoblastic Leukemia research2.7%
  • Other58.4%

Coauthors

All papers

Open in search
  1. Functional genomic landscape of acute myeloid leukaemia

    Authors: Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly, Beth Wilmot, Stephen E. Kurtz, Samantha L. Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Melissa L. Abel, Anupriya Agarwal, Aurora Blucher, Uma Borate, Jade Bryant, Russell T. Burke, Amy Carlos, Richie Carpenter, Joseph Carroll, Bill H. Chang, Cody Coblentz, Amanda d’Almeida, Rachel J. Cook, Alexey V. Danilov, Kim-Hien T. Dao, Michie Degnin, Deirdre DeVine, James Dibb, David K. Edwards, Christopher A. Eide, Isabel A. English, Jason Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, Andy Kaempf, Jessica Leonard, Chenwei Lin, Selina Qiuying Liu, Pierrette Lo, Marc Loriaux, Samuel B. Luty, Tara A. Macey, Jason D. MacManiman, Jacqueline Martinez, Motomi Mori, Dylan Nelson, Ceilidh Nichols, Jill Peters, Justin Ramsdill, Angela Rofelty, Robert Schuff, Robert P. Searles, Erik Segerdell, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jake Wagner, Kevin Watanabe‐Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Denise C. Connolly, Michael W. Deininger, Leylah Drusbosky, Christopher S. Hourigan, Craig T. Jordan, Patricia Kropf, Tara L. Lin, Micaela Martínez, Bruno C. Medeiros, Rachel R. Pallapati, Daniel A. Pollyea, Ronan Swords, Justin M. Watts, Scott J. Weir, David L. Wiest, Ryan M. Winters, Shannon K. McWeeney, Brian Druker - Nature 2018 cited by 1,476

  2. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Authors: Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 cited by 1,510

  3. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Authors: Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson‐Viitanen, Iphigenia L. Koumenis, William Sun, Victor Sandor, Hagop M. Kantarjian - New England Journal of Medicine 2012 cited by 2,050

  4. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

    Authors: Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa L. Abel, Anupriya Agarwal, Sammantha Avaylon, Erik Benton, Aurora Blucher, Uma Borate, Theodore P. Braun, Jordana Brown, Jade Bryant, Russell T. Burke, Amy Carlos, Bill H. Chang, Hyun Cho, Stephen Christy, Cody Coblentz, Aaron Cohen, Amanda d’Almeida, Rachel J. Cook, Alexey V. Danilov, Kim‐Hien T. Dao, Michie Degnin, James Dibb, Christopher A. Eide, Isabel A. English, Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil K. Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyun-Jung Lee, Jessica Leonard, Chenwei Lin, Evan Lind, Selina Qiuying Liu, Pierrette Lo, Marc Loriaux, Samuel B. Luty, Julia E. Maxson, Tara A. Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Kyle A. Romine, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert P. Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela Martínez, Rachel R. Pallapati, Daniel A. Pollyea, Anthony D. Pomicter, Justin M. Watts, Scott J. Weir, Brian Druker, Shannon K. McWeeney, Jeffrey Tyner - Cancer Cell 2022 cited by 368

  5. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Authors: Andreas Hochhaus, Richard A. Larson, François Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, Michael W. Deininger, Francisco Cervantes, Satoko Fujihara, Christine-Elke Ortmann, Hans D. Menssen, Hagop Kantarjian, Stephen G. O’Brien, Brian Druker - New England Journal of Medicine 2017 cited by 1,259

  6. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    Authors: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 cited by 467

  7. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  8. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 cited by 583

  9. AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Authors: Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu, Christopher A. Eide, Victor M. Rivera, Frank Wang, Lauren T. Adrian, Tianjun Zhou, Wei-Sheng Huang, Qihong Xu, Chester A. Metcalf, Jeffrey Tyner, Marc Loriaux, Amie S. Corbin, Scott Wardwell, Yaoyu Ning, Jeffrey Keats, Yihan Wang, Raji Sundaramoorthi, Mathew Thomas, Dong Zhou, J. T. Snodgrass, Lois Commodore, Tomi K. Sawyer, David C. Dalgarno, Michael W. Deininger, Brian Druker, Tim Clackson - Cancer Cell 2009 cited by 1,247

  10. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  11. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Authors: Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong‐Wook Kim, Iryna Dyagil, Nataliia Glushko, Dragana Milojković, Philipp le Coutre, Valentín García‐Gutiérrez, Laurence Reilly, Allison Jeynes-Ellis, Eric Leip, Nathalie Bardy‐Bouxin, Andreas Hochhaus, Tim H. Brümmendorf - Journal of Clinical Oncology 2017 cited by 493

  12. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

    Authors: Alyssa Carey, David K. Edwards, Christopher A. Eide, Laura F. Newell, Elie Traer, Bruno C. Medeiros, Daniel A. Pollyea, Michael W. Deininger, Robert H. Collins, Jeffrey Tyner, Brian Druker, Grover C. Bagby, Shannon K. McWeeney, Anupriya Agarwal - Cell Reports 2017 cited by 270

  13. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

    Authors: Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage, Orlando Antelope, Nadeem A. Vellore, Hein Than, Anna Reister Schultz, Phillip M. Clair, Amber D. Bowler, Anthony D. Pomicter, Dongqing Yan, Anna V. Senina, Qiang Wang, Todd W. Kelley, Philippe Szankasi, Michael C. Heinrich, Jeffrey Tyner, Delphine Réa, Jean-Michel Cayuela, Dong‐Wook Kim, Cristina E. Tognon, Thomas O’Hare, Brian Druker, Michael W. Deininger - Cancer Cell 2019 cited by 245

  14. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

    Authors: for the COMFORT-I investigators, Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark M. Jones, Deanna Kornacki, Kang Sun, Hagop M. Kantarjian - Journal of Hematology & Oncology 2017 cited by 427

  15. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Authors: Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger, BFORE study investigators - Leukemia 2022 cited by 141

  16. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

    Authors: Amy Burd, Ross L. Levine, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael W. Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, James M. Foran, Tara L. Lin, Brian Ball, Michael Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Jo-Anne Vergilio, Timothy J. Brennan, Christine Vietz, Eric A. Severson, Molly Miller, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy F. Chen, Mona Stefanos, Brian Druker, John C. Byrd - Nature Medicine 2020 cited by 192

  17. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions

    Authors: Afaf E.G. Osman, Michael W. Deininger - Blood Reviews 2021 cited by 202

  18. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

    Authors: Nicholas C.P. Cross, Thomas Ernst, Susan Branford, Jean‐Michel Cayuela, Michael W. Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Kateřina Machová Poláková, Jerald P. Radich, Rüdiger Hehlmann, Andreas Hochhaus, Jane F. Apperley, Simona Soverini - Leukemia 2023 cited by 103

  19. The molecular biology of chronic myeloid leukemia

    Authors: Michael W. Deininger, John M. Goldman, Junia V. Melo - Blood 2000 cited by 1,620

  20. The development of imatinib as a therapeutic agent for chronic myeloid leukemia

    Authors: Michael W. Deininger, Elisabeth Buchdunger, Brian Druker - Blood 2004 cited by 1,245

  21. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

    Authors: Amie S. Corbin, Anupriya Agarwal, Marc Loriaux, Jörge E. Cortes, Michael W. Deininger, Brian Druker - Journal of Clinical Investigation 2010 cited by 763

  22. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

    Authors: Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty, Thomas G.P. Bumm, Curtis L. Petersen, Shirin Doratotaj, Kavin B. Vasudevan, Dorian LaTocha, Fei Yang, Richard D. Press, Marc Loriaux, Heike L. Pahl, Richard T. Silver, Anupriya Agarwal, Thomas O’Hare, Brian Druker, Grover C. Bagby, Michael W. Deininger - Blood 2011 cited by 287

  23. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

    Authors: Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, Delphine Réa, Jörge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver G. Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gómez-Garcı́a de Soria, Philipp le Coutre, François‐Xavier Mahon, Jeroen J. W. M. Janssen, Michael W. Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang - Leukemia 2023 cited by 47

  24. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, Dale L. Bixby, Michael J. Mauro, Ian W. Flinn, Thomas O’Hare, Simin Hu, Narayana I. Narasimhan, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian Druker, Michael W. Deininger, Moshe Talpaz - New England Journal of Medicine 2012 cited by 770